Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
We are pleased to let you know that Magnus Gustafsson from Biovian will speak about New Biologicals at “New Horizons in Biologics & Bioprocessing digital event”, on December 17th at 8:45 (CET). TALK: Manufacture and …
Discussion with Scientist Pekka Puolasmaa and Project Manager Tuomas Nikula. The goal of gene therapy is to treat or cure severe diseases by carrying genetic material to the target cells to repair the incorrect or …
In this video the CEO of Biovian, Knut Ringbom, presents an overview of the year 2020, especially discussing the latest developments in the company. “Over the last year, we have experienced a lot of positive …
